Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

With this in mind, let's check out two no-brainer biotech stocks to buy right now. Moderna is an mRNA specialist, and this technology is delivering compelling results across a pipeline of late ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Foroohar, a top biotech analyst, has slapped an “underperform” rating on Moderna, the sector’s brightest star in the heady decadelong boom that culminated in the industry’s rally to combat ...

As a result of the stop work order, Vaxart said it had been forced to lay off 10% of its workforce. The company entered the ...

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore more details here.

Moderna Inc., a biotechnology and pharmaceutical company reorienting its business for a post-pandemic age, awarded almost $17 ...